242 related articles for article (PubMed ID: 15738529)
1. Prostate cancer chemotherapy: emerging from the shadows.
Roth BJ
J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
[No Abstract] [Full Text] [Related]
2. [Treatment of locally spread prostate cancer].
Tammela T
Duodecim; 2005; 121(16):1779-82. PubMed ID: 16268225
[No Abstract] [Full Text] [Related]
3. Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?
Akaza H
Can J Urol; 2005 Feb; 12 Suppl 1():77-80. PubMed ID: 15780172
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?
Bellmunt J
Eur Urol; 2009 Jun; 55(6):1310-2. PubMed ID: 18778888
[No Abstract] [Full Text] [Related]
5. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
6. Therapies in development for castrate-resistant prostate cancer.
Harzstark AL; Ryan CJ
Expert Rev Anticancer Ther; 2008 Feb; 8(2):259-68. PubMed ID: 18279066
[TBL] [Abstract][Full Text] [Related]
7. Intermittent androgen deprivation therapy: conventional wisdom versus evidence.
Tombal B
Eur Urol; 2009 Jun; 55(6):1278-80. PubMed ID: 19303201
[No Abstract] [Full Text] [Related]
8. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
Morris MJ; Kelly WK; Slovin S; Ryan C; Eicher C; Heller G; Scher HI
J Urol; 2007 Dec; 178(6):2378-83; discussion 2383-4. PubMed ID: 17936848
[TBL] [Abstract][Full Text] [Related]
9. Update in systemic therapy of prostate cancer: improvement in quality and duration of life.
Vaishampayan U; Hussain M
Expert Rev Anticancer Ther; 2008 Feb; 8(2):269-81. PubMed ID: 18279067
[TBL] [Abstract][Full Text] [Related]
10. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.
Grothey A; Sargent DJ
J Clin Oncol; 2005 May; 23(15):3311-3. PubMed ID: 15908645
[No Abstract] [Full Text] [Related]
11. Rebuttal from authors re: Joaquim Bellmunt. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 2009;55:1310-2.
Italiano A; Fizazi K
Eur Urol; 2009 Jun; 55(6):1313-4. PubMed ID: 18849106
[No Abstract] [Full Text] [Related]
12. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
Ward JF
Nat Clin Pract Urol; 2006 Jun; 3(6):310-1. PubMed ID: 16763642
[No Abstract] [Full Text] [Related]
13. [Early versus late hormonal treatment in advanced prostate cancer].
Allepuz Losa C; Gil MartÃnez P; Gil Sanz MJ; Rioja Sanz LA
Actas Urol Esp; 1999; 23(7):557-64. PubMed ID: 10488608
[No Abstract] [Full Text] [Related]
14. Recent advances in the hormonal treatment of breast cancer.
Boughey JC; Buzdar AU; Hunt KK
Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
[No Abstract] [Full Text] [Related]
15. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Sridhar SS; Hotte SJ; Chin JL; Hudes GR; Gregg R; Trachtenberg J; Wang L; Tran-Thanh D; Pham NA; Tsao MS; Hedley D; Dancey JE; Moore MJ
Am J Clin Oncol; 2010 Dec; 33(6):609-13. PubMed ID: 20042973
[TBL] [Abstract][Full Text] [Related]
16. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
Di Silverio F; Serio M; Costantini A
J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846
[No Abstract] [Full Text] [Related]
17. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M
Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
[TBL] [Abstract][Full Text] [Related]
18. Hormone-refractory prostate cancer: what have we learned?
Wirth MP
BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
[No Abstract] [Full Text] [Related]
19. Selection bias is not a good reason for advising more than 5 years of adjuvant hormonal therapy for all patients with locally advanced prostate cancer treated with radiotherapy.
Collette L; Studer UE
J Clin Oncol; 2009 Nov; 27(33):e201-2; author reply e204. PubMed ID: 19786659
[No Abstract] [Full Text] [Related]
20. [What is the best strategy of hormonal therapy in the treatment of locally advanced prostate cancer?].
Ehara H; Nakano M; Deguchi T
Hinyokika Kiyo; 2006 Jun; 52(6):473-7. PubMed ID: 16848361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
